Investigators found sex and racial differences in the risk for end-stage kidney disease among patients with CKD anemia.
In a study, older hemodialysis patients performing resistance exercise for 24 weeks saw their iron bioavailability increase.
For patients with chronic kidney disease (CKD) receiving erythropoiesis-stimulating agents (ESAs), achieving hemoglobin (Hb) levels higher than guideline-recommended target range is associated with a small but potentially clinically significant improvement in fatigue, although not in the ability to perform usual daily work or other activities. In a systematic review and meta-analysis of 15 randomized trials…
This study investigated intravenous iron in hemodialysis patients with functional iron deficiency anemia.
Infection with the virus that causes COVID-19, coupled with use of erythropoiesis-stimulating agents may result in additive prothrombotic effects, according to the authors.
In 2 Japanese trials of nondialysis patients, molidustat proved noninferior to darbepoetin alfa, an erythropoiesis-stimulating agent, in correcting and maintaining hemoglobin levels over 36 weeks.
Positive test result does not confirm immunity to the virus, and test is not meant to diagnose illness.
In separate active comparator studies, roxadustat achieved hemoglobin correction in CKD patients and maintained hemoglobin within target range in hemodialysis patients at least as well as darbepoetin alfa over 24 weeks.
In a study of patients on dialysis, investigators found no higher risk for retinal hemorrhages and other ophthalmic problems among roxadustat-treated patients compared with patients receiving darbepoetin alfa.
Less than half of blood donors with low ferritin at index achieved adequate stores within 12 months.